Cytox is developing a diagnostic test and therapeutic cures for Alzheimer’s Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases.

Status current

Associated Fund Advantage Growth Fund,
UK Innovation & Science Seed Fund

Sector Medical / Biotechnology


Associated Team Members

Relevant News

Cytox Plans US Clinical Launch for Early-Stage Alzheimer's Test While Courting Pharma Partners

  May 03, 2017 Justin Petrone British molecular diagnostics company Cytox plans to make…

read more

More Companies in Medical / Biotechnology